About polypid ltd - PYPD
PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.
PYPD At a Glance
PolyPid Ltd.
18 Hasivim Street
Petach Tikva, HaMerkaz 495376
| Phone | 972-74-719-5700 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -34,169,000.00 | |
| Sector | Health Technology | Employees | 75 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PYPD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 7.20 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.924 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.046 |
PYPD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -455,586.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PYPD Liquidity
| Current Ratio | 1.968 |
| Quick Ratio | 1.825 |
| Cash Ratio | 1.696 |
PYPD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -143.788 |
| Return on Equity | -366.286 |
| Return on Total Capital | -248.159 |
| Return on Invested Capital | -322.121 |
PYPD Capital Structure
| Total Debt to Total Equity | 25.481 |
| Total Debt to Total Capital | 20.306 |
| Total Debt to Total Assets | 12.534 |
| Long-Term Debt to Equity | 5.896 |
| Long-Term Debt to Total Capital | 4.699 |